MD Anderson Cancer Center的动态

The 2024 American Association for Cancer Research Special Conference in Cancer Research brought together more than 600 experts to focus on pancreatic cancer research, promote a better understanding of the disease, and find better ways to treat it. The topics, which included cachexia, immunology and immunotherapy, and the tumor microenvironment, demonstrated that promising work is being performed in the labs and moving into clinical settings. Hope is on the way. https://bit.ly/3BCSRB3 #PancreaticCancer #Oncology #CancerResearch

?? Revolutionizing Cancer Treatment: The Personalized Medicine Approach Every type of cancer is a puzzle, unique in its complexity. Discover how blood-based biomarkers could be the key to unlocking effective and tailored therapies for cancer patients undergoing immunotherapy. Our latest article by Janniek Mors explores the revolutionising power of personalised medicine in cancer treatment. Read more about this groundbreaking approach, where each patient's journey is as individual as the pieces of a puzzle. https://lnkd.in/gqSSxJX5 #VUSci #biomarkers #cancerresearch #personalizedmedicine #editorial

?? Hot off the press! We are excited to announce the release of our latest article shedding light on the groundbreaking research conducted by our talented PhD candidate, Astrid Van den Eynde. Delving into the intricacies of CAR NK cells targeting tumor cells and cancer-associated fibroblasts in both pancreatic and colorectal cancer, this work marks a significant stride in oncological advancement. ???? Proudly supported by Kom op tegen Kanker (vzw). ?? Dive into the full article through the link below. Jonas Van Audenaerde Evelien Smits #CancerResearch #CARNK #Celltherapy

Thanks to Dr. Ramaprasad Srinivasan and Dr. Andrea Apolog for sharing with us how research at the National Cancer Institute is tackling rare #kidneycancer tumors. Read more on our blog: https://bit.ly/49EdNnJ #rarecancer #cancerresearch #kidneycancerawarenessmonth

Breast Cancer Blood Test Hailed As A Breakthrough! A new type of “ultra-sensitive” blood test can predict if breast cancer will return in high-risk patients long before they relapse and symptoms show up on scans, according to scientists at the Institute of Cancer Research (ICR) in London, England... https://bit.ly/3T9NteQ #cancer #breastcancer #bloodcancer #cancersucks #health #cancersurvivor #c #cancerawareness #cancerfighter #oncology #oncologia #chemotherapy #cancerwarrior #cancersupport #cancerresearch #chemo #cancertreatment

?? Today let's focus on ovarian cancer with this insightful article from the Mayo Clinic Comprehensive Cancer Center Blog, exploring the latest treatments and groundbreaking research! ?? https://hubs.li/Q02G0dK80 #ClinicalTrial #MayoClinic #OvarianCancer

Breast Cancer Blood Test Hailed As A Breakthrough! A new type of “ultra-sensitive” blood test can predict if breast cancer will return in high-risk patients long before they relapse and symptoms show up on scans, according to scientists at the Institute of Cancer Research (ICR) in London, England... https://bit.ly/3T9NteQ #cancer #breastcancer #bloodcancer #cancersucks #health #cancersurvivor #c #cancerawareness #cancerfighter #oncology #oncologia #chemotherapy #cancerwarrior #cancersupport #cancerresearch #chemo #cancertreatment

??? Breast Cancer Awareness ??? Exciting developments are happening in the fight against early-stage breast cancer! A groundbreaking collaboration between Caris Life Sciences and the ECOG-ACRIN Cancer Research Group is leveraging genomics and AI to tackle recurrence. This initiative exemplifies the power of precision medicine and innovative solutions—values that resonate deeply with us at C3 Medical. By harnessing the potential of genomics, we can develop more effective treatments and improve patient outcomes. Let’s champion these advancements together! Read more about this inspiring collaboration and its implications for breast cancer treatment. https://lnkd.in/eEz_WyUn #BreastCancerAwareness #Genomics #AI #Innovation #C3Medical

Summary of our paper on combining JAK inhibitors with anti-PD1 for lung cancer - Andy Minn E. John Wherry Divij Mathew Melina Marmarelis Joshua Bauml #Cancer #LCSM #NSCLC #CancerResearch #OncoDaily #Oncology

#cancerresearch #oncology #cancertreatment https://lnkd.in/gnnk5qkp Abstract As #angiogenesis was recognized as a core hallmark of #cancer #growth and #survival, several strategies have been implemented to target the tumour vasculature. Yet to date, attempts have rarely been so diverse, ranging from vessel growth inhibition and destruction to vessel normalization, reprogramming and vessel growth promotion. Some of these strategies, combined with standard of care, have translated into improved cancer therapies, but their successes are constrained to certain cancer types. This Review provides an overview of these vascular targeting approaches and puts them into context based on our subsequent improved understanding of the tumour vasculature as an integral part of the tumour microenvironment with which it is functionally interlinked. This new knowledge has already led to dual targeting of the vascular and immune cell compartments and sets the scene for future investigations of possible alternative approaches that consider the vascular link with other tumour microenvironment components for improved cancer therapy.